Abstract：
Glucagon-like-peptide-1 (GLP-1) agonists are an emerging class of medications used to manage type 2 diabetes mellitus (T2DM) and weight loss, with demonstrated efficacy in reducing hemoglobin A1c levels, body mass index, and adverse cardiovascular events. While previous studies have reviewed notable cutaneous adverse effects with other antidiabetic medications, little is known about GLP-1 agonist-induced cutaneous reactions. Nevertheless, rare but significant cutaneous adverse reactions have been reported, including but not limited to dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions. As GLP-1 induced cutaneous reactions are diverse, diagnosis requires clinical suspicion, thorough history-taking, and supportive histopathological findings when available. Management involves cessation of the offending agent with a tailored regimen to address inflammatory and/or immunogenic etiologies as well as irritative symptoms. This review aims to consolidate available information from case reports and case series regarding rare skin-related adverse outcomes due to GLP-1 use, aiming to provide a comprehensive overview of the presentation, pathogenesis, and management for dermatologists and other clinicians.
摘要：
胰高血糖素样肽-1（GLP-1）激动剂是一类用于治疗2型糖尿病（T2DM）和体重减轻的新兴药物。具有降低血红蛋白A1c水平的功效，身体质量指数,和不良心血管事件。虽然以前的研究已经回顾了其他抗糖尿病药物的显着皮肤不良反应，对GLP-1激动剂诱导的皮肤反应知之甚少。然而，已经报道了罕见但显著的皮肤不良反应，包括但不限于皮肤过敏反应，嗜酸性脂膜炎,大疱性类天疱疮,和精神上的药疹。由于GLP-1诱导的皮肤反应是多种多样的，诊断需要临床怀疑，彻底的历史，以及可用的支持性组织病理学发现。管理涉及用定制的方案停止冒犯剂,以解决炎性和/或免疫原性病因以及刺激性症状。本综述旨在整合病例报告和病例系列中有关因使用GLP-1引起的罕见皮肤相关不良结局的现有信息。旨在全面概述演示文稿，发病机制，以及皮肤科医生和其他临床医生的管理。
